Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

10.3K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
10.3K
Tumor Progression02:07

Tumor Progression

7.9K
Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...
7.9K
Tumor Progression02:07

Tumor Progression

3.6K
3.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

5.1K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
5.1K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

1.7K
1.7K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Regulation of Laser-Deposited Silver Microstructures on Ceramic Surfaces and Their Effects on Electrical Conductivity.

Micromachines·2026
Same author

Altered effective connectivity in internet gaming disorder and its predictive value for clinical severity: A spectral DCM study.

Brain research bulletin·2026
Same author

Severity-dependent alterations of functional network segregation and integration in tobacco use disorder.

Progress in neuro-psychopharmacology & biological psychiatry·2026
Same author

Artificial intelligence for detecting fetal orofacial clefts and advancing medical education.

Nature communications·2026
Same author

Germination Dynamics and Seedling Development of Wheat Under Various Ionic Salt Stresses.

Plants (Basel, Switzerland)·2026
Same author

Mitochondrial Dysfunction in Myoblasts: A TSPO-Dependent Mechanism of Sarcopenia.

The journals of gerontology. Series A, Biological sciences and medical sciences·2026

Related Experiment Video

Updated: Apr 3, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.7K

Correlation Between Nuclear Factor E2-Related Factor 2 Expression and Gastric Cancer Progression.

Hongyu Zheng1, Zhiwei Nong2, Guohao Lu3

  • 1Department of Ultrasound, The People's Hospital of Guangxi Zhuang Autonomous Region, Nanning, Guangxi, China (mainland).

Medical Science Monitor : International Medical Journal of Experimental and Clinical Research
|September 28, 2015
PubMed
Summary

Nuclear factor E2-related factor 2 (Nrf2) expression in gastric cancer correlates with poor prognosis and chemo-resistance. Nrf2 positivity indicates a higher risk of invasive disease and reduced survival rates.

More Related Videos

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

6.3K

Related Experiment Videos

Last Updated: Apr 3, 2026

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT
10:28

Gene Regulation and Targeted Therapy in Gastric Cancer Peritoneal Metastasis: Radiological Findings from Dual Energy CT and PET/CT

Published on: January 22, 2018

11.7K
Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer
06:21

Author Spotlight: Genetic Profiling for Fluorouracil Response in Gastric Cancer

Published on: May 10, 2024

1.4K
Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer
07:50

Genome-Wide Analysis of DNA Methylation in Gastrointestinal Cancer

Published on: September 18, 2020

6.3K

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Nuclear factor E2-related factor 2 (Nrf2) is a transcription factor involved in cellular defense mechanisms against oxidative stress.
  • Nrf2 regulates antioxidant and detoxification genes, playing a role in both normal cell protection and cancer development.
  • The role of Nrf2 in gastric cancer has not been previously established.

Purpose of the Study:

  • To investigate the expression of Nrf2 in gastric cancer tissues.
  • To determine the correlation between Nrf2 expression and clinicopathological features.
  • To assess the prognostic significance of Nrf2 in gastric cancer patients.

Main Methods:

  • Immunohistochemical (IHC) staining was performed on 175 gastric carcinoma tissue samples.
  • Statistical analyses, including chi-square, Fisher's exact, Mann-Whitney U, Kaplan-Meier, and log-rank tests, were used.
  • Correlation with clinical indexes and survival rates was analyzed.

Main Results:

  • Nrf2 was predominantly expressed in the nuclei of gastric cancer cells.
  • Nrf2 expression significantly correlated with tumor size, invasive depth, lymph node metastasis, and invasion.
  • Nrf2-positive patients exhibited significantly lower survival rates and chemo-resistance to 5-fluorouracil (5-FU).

Conclusions:

  • Nrf2 expression is positively associated with invasive gastric cancer.
  • Nrf2 serves as a potential predictive biomarker for unfavorable prognosis in gastric cancer.
  • Targeting Nrf2 may offer therapeutic strategies for improving outcomes in gastric cancer.